No End In Sight For M&A As Medtechs Adapt To The “New Normal”
Executive Summary
The global medtech industry may be facing slow growth, rising regulatory demands and not exactly free-flowing venture capital investment. But EY finds reasons for optimism and sees opportunities for companies able to cope with the changes and move with alacrity.
You may also be interested in...
Medtech’s Role In The Carbon Neutral Challenge To Counter Climate Change – The UK View
“Sustainability executive” is a new job role for a new era. The UK’s largest healthtech industry association has appointed one, and many medtech companies in every geography might eventually do likewise, as the drive for nations to achieve carbon neutrality picks up pace. Medtech Insight spoke to the ABHI’s new incumbent Addie MacGregor and director of value and access Luella Trickett to gauge the size of the task before the medtech industry.
‘Patchy’ UK AHSNs To Be Addressed Ahead Of 2023 Relicensing
A new remit for the NHS’ innovation vehicles, hopes for Integrated Care Systems and a new diagnostics trends report from Deloitte were on the agenda at a UK life sciences sector policy conference.
Tunbridge: Global CABs Are Vital For Global Device Regulation
The role and purpose of medical device regulation is now better understood than at any time in its history, and regulators are no longer seen as gatekeepers preventing business from happening. Graeme Tunbridge, formerly at the MHRA and now a senior VP at leading conformity assessment body BSI, is a champion of the climate of inclusivity.